These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30774407)

  • 1. Profile of plecanatide in the treatment of chronic idiopathic constipation: design, development, and place in therapy.
    Sharma A; Herekar AA; Bhagatwala J; Rao SS
    Clin Exp Gastroenterol; 2019; 12():31-36. PubMed ID: 30774407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation.
    Rao SSC
    Therap Adv Gastroenterol; 2018; 11():1756284818777945. PubMed ID: 29942351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plecanatide for the treatment of chronic idiopathic constipation in adult patients.
    Bassotti G; Usai Satta P; Bellini M
    Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1019-1026. PubMed ID: 31575291
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.
    Shah ED; Kim HM; Schoenfeld P
    Am J Gastroenterol; 2018 Mar; 113(3):329-338. PubMed ID: 29380823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit-Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation.
    Miner PB
    Drug Saf; 2019 May; 42(5):603-615. PubMed ID: 30649746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome.
    Miner PB
    Expert Opin Pharmacother; 2018 Feb; 19(2):177-183. PubMed ID: 29376436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog.
    Brancale A; Shailubhai K; Ferla S; Ricci A; Bassetto M; Jacob GS
    Pharmacol Res Perspect; 2017 Apr; 5(2):e00295. PubMed ID: 28357122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome.
    Love BL
    Am J Med; 2019 May; 132(5):572-575. PubMed ID: 30550753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation.
    Miner PB; Koltun WD; Wiener GJ; De La Portilla M; Prieto B; Shailubhai K; Layton MB; Barrow L; Magnus L; Griffin PH
    Am J Gastroenterol; 2017 Apr; 112(4):613-621. PubMed ID: 28169285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plecanatide: First Global Approval.
    Al-Salama ZT; Syed YY
    Drugs; 2017 Apr; 77(5):593-598. PubMed ID: 28255961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.
    Miner PB
    Expert Rev Gastroenterol Hepatol; 2020 Feb; 14(2):71-84. PubMed ID: 31985305
    [No Abstract]   [Full Text] [Related]  

  • 12. The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials.
    Moshiree B; Schoenfeld P; Franklin H; Rezaie A
    Clin Ther; 2022 Jan; 44(1):98-110.e1. PubMed ID: 35086735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases.
    Jarmuż A; Zielińska M; Storr M; Fichna J
    Neurogastroenterol Motil; 2015 Aug; 27(8):1057-68. PubMed ID: 25930667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH; Luthin DR
    Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plecanatide Is Effective and Safe in the Treatment for Chronic Idiopathic Constipation: Results of a Phase II Trial.
    Barish C; Dorn S; Fogel RP; Patel R; Rosenberg J
    Dig Dis Sci; 2021 Feb; 66(2):537-540. PubMed ID: 32185662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation.
    DeMicco M; Barrow L; Hickey B; Shailubhai K; Griffin P
    Therap Adv Gastroenterol; 2017 Nov; 10(11):837-851. PubMed ID: 29147135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of plecanatide in the treatment of chronic idiopathic constipation.
    Islam BN; Sharman SK; Browning DD
    Int J Gen Med; 2018; 11():323-330. PubMed ID: 30127634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.
    Shailubhai K; Palejwala V; Arjunan KP; Saykhedkar S; Nefsky B; Foss JA; Comiskey S; Jacob GS; Plevy SE
    World J Gastrointest Pharmacol Ther; 2015 Nov; 6(4):213-22. PubMed ID: 26558155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of plecanatide in patients with chronic idiopathic constipation: long-term evidence from an open-label study.
    Barish CF; Griffin P
    Curr Med Res Opin; 2018 Apr; 34(4):751-755. PubMed ID: 29343131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.